You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
Jean-Laurent Casanova, M.D., Ph.D., is a professor and Head of Laboratory at the Rockefeller University, Senior Attending Physician at the Rockefeller University Hospital and Investigator at the Howard Hughes Medical Institute. He is a pediatrician and immunologist by training, and in practice, has become an internationally renowned human geneticist investigating infectious diseases. Dr. Casanova discovered that life-threatening infectious diseases from childhood may be caused by single-gene inborn errors of immunity.
Dr. Casanova was an international research scholar with the Howard Hughes Medical Institute from 2005 to 2008 and was elected to the European Molecular Biology Organization in 2005. He has also received numerous awards throughout his career, including the Professor Lucien Dautrebande Pathophysiology Foundation Prize (2004), Richard Lounsbery Award (2008), E. Mead Johnson Award from the Society for Pediatric Research (2010), InBev-Baillet Latour Health Prize (2011), Ilse & Helmut Wachter Foundation Award and the Milstein Award (2012), Robert Koch Prize and the Sanofi-Institut Pasteur Award (2014) and was elected as a Foreign Associate of the National Academy of Sciences of the USA (2015).
Roy F. Chemaly, M.D., M.P.H., is a professor in the department of infectious diseases, infection control and employee health, division of internal medicine at The University of Texas, MD Anderson Cancer Center. Dr. Chemaly is board certified, specializing in infectious diseases, and has published extensively on infections in immunocompromised hosts such as stem cell transplant patients. He is also the director of Infection Control and Antimicrobial Stewardship Programs.
John DeVincenzo, M.D., is a practicing pediatric infectious disease specialist, Professor of Pediatrics and Professor of Microbiology, Immunology, and Biochemistry at the University of Tennessee School of Medicine. His research focuses on understanding the pathogenesis of Respiratory Syncytial Virus (RSV) directly in children and using this understanding to develop therapeutic and prevention strategies against this virus. He is the author of over 140 original published abstracts and papers on this subject. Dr. DeVincenzo has conducted numerous clinical trials in children defining the role of prevention and therapeutic applications of monoclonal antibodies targeting RSV in infants and the immunosuppressed.
Erwin W. Gelfand, M.D., Professor of Pediatrics at National Jewish Health in Denver, CO. For more than four decades, Dr. Gelfand has enjoyed the ability to combine interests in clinical susceptibility to disease and the diagnosis and treatment of immune deficiency and allergic diseases. Born in Montreal, he received his medical school degree (MDCM) from McGill University and subsequent Pediatric training at Children’s Hospital in Boston and Fellowship in Immunology there and from Harvard University. He is board-certified in Pediatrics and a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCP-C). At National Jewish Health in Denver, where he was Chairman of Pediatrics for 30 years and a Professor of Immunology and Pediatrics at the University of Colorado School of Medicine, he directed a major national referral center for patients with uncontrolled atopic disease and immune disorders. In a number of these patients, it became increasingly clear that patients with severe atopic disease, especially atopic dermatitis, may harbor a significant monoallelic mutation in an immune system pathway gene. Thus, immune deficiency diseases masquerading as an allergic disease are being revealed. He carried out some of the earliest bone marrow transplants in patients with immune deficiency and was a leader in the use of immunoglobulin therapy not only in immunodeficiency but in autoimmune and inflammatory conditions. With training as an immunologist, his current interests are focused on those unique diseases where genetic evaluation holds the key. He has published almost 800 articles in leading peer-reviewed journals including Science, Nature, Immunity, Journal of Experimental Medicine, and Journal of Clinical Investigation, and is the recipient of continuous grant support from the NIH and numerous awards. Perhaps most importantly, he has trained more than 100 post-doctoral fellows in his laboratory, many going on to be leaders in their own countries.
Jordan S. Orange, M.D., Ph.D., is chair of pediatrics at Columbia University College of Physicians and Surgeons and pediatrician-in-chief of New York-Presbyterian/Morgan Stanley Children’s Hospital. Dr. Orange is a board-certified pediatrician and allergist/immunologist with a clinical specialty in primary immunodeficiency disease. Dr. Orange has focused his research efforts upon Primary Immunodeficiency, Immunoglobulin, NK cell deficiency and the cell biology of human NK cell defenses.
E. Richard Stiehm, M.D., is a distinguished research professor of pediatrics emeritus at the University of California, Los Angeles. Dr. Stiehm served as Chief of the Division of Pediatric Immunology/Allergy/Rheumatology from 1969 to 2003 and a graduate of the University of Wisconsin and its Medical School. Dr. Stiehm has been the training director for over 50 fellows in allergy and immunology and his research interests include primary immunodeficiency, neonatal immunology, immunoglobulin therapy, pediatric rheumatology and pediatric HIV infection.
He is the author of over 500 articles and chapters and is the chief editor of Immunologic Disorders in Infants and Children editions I through V and an editor of Stiehm’s Immunodeficiency (in press).